A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
about
Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.Arsenic trioxide-mediated suppression of miR-182-5p is associated with potent anti-oxidant effects through up-regulation of SESN2.A highlight on Sonic hedgehog pathway.A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system
P2860
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
A phase II trial of arsenic tr ...... tients with malignant gliomas.
@en
type
label
A phase II trial of arsenic tr ...... tients with malignant gliomas.
@en
prefLabel
A phase II trial of arsenic tr ...... tients with malignant gliomas.
@en
P2093
P2860
P1476
A phase II trial of arsenic tr ...... tients with malignant gliomas.
@en
P2093
Irene Helenowski
James Chandler
Jeffrey Raizer
Katie McCarthy
Kenji Muro
Leanne Fountas
Maryanne Marymont
Minesh Mehta
Priya Kumthekar
Robert Levy
P2860
P2888
P304
P356
10.1007/S11060-017-2469-X
P577
2017-05-16T00:00:00Z
P6179
1085422047